[Chinese expert guidance on overall application of lenvatinib in hepatocellular carcinoma].

Lenvatinib mesylate is an oral receptor tyrosine kinase inhibitor against targets of vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor α, stem cell growth factor receptor, and rearranged during transfection, et al. Lenvatinib has been approved by the National Medical Products Administration of China on September 4, 2018, for the first-line treatment of patients with unresectable hepatocellular carcinoma who have not received systematic treatment before. Up to February 2023, Lenvatinib has been listed in China for more than 4 years, accumulating a series of post-marketing clinical research evidences. Based on the clinical practice before and after the launch of lenvatinib and referring to the clinical experience of other anti-angiogenesis inhibitors, domestic multidisciplinary experts and scholars adopt the Delphi method to formulate the Chinese Expert Guidance on Overall Application of Lenvatinib in Hepatocellular Carcinoma after repeated discussions and revisions, in order to provide reference for reasonable and effective clinical application of lenvatinib for clinicians.

Maxillofacial Injury Severity Score: proposal of a new scoring system.

In this study a new injury severity score system, the Maxillofacial Injury Severity Score (MFISS), was developed to evaluate the characteristics of injury from maxillofacial trauma. Nine hundred and two cases of maxillofacial trauma were included in this study to evaluate injury severity using the MFISS, which was designed on the basis of Abbreviated Injury Scale, 1990 revision (AIS-90), and defined as the product of the sum of the three highest maxillofacial AIS scores and the sum of the injury severity scores for three maxillofacial functional parameters, malocclusion (MO), limited mouth opening (LMO), and facial deformity (FD). The correlation analysis was undertaken with the dependent factor of cost and number of days of stay in hospital. The results demonstrated a significant difference (P < 0.01) between bone and soft-tissue injuries and among various regional fractures. There was correlation (P < 0.01) between the MFISS and the cost of treatment and days of stay in hospital. The newly established MFISS thus characterizes maxillofacial injury severity while reflecting the management costs and treatment complexity.

[Compounds from roots of Chirita fimbrisepala Hand.-Mazz].

OBJECTIVE: To study the chemical constituents the roots of Chirita fimbrisepala. METHOD: The constituents were extracted with solvent, separated and purified with chromatographic methods, identified by NMR, MS, UV, IR and physical-chemical constants. RESULT: Three flavonoids mahuangchiside(I), hispidulin (II) and kaempferol(III) were isolated with daucosteral(IV). CONCLUSION: I is a new compound elucidated as hispidulin-7-O-beta-D-xylopyranosyl-(1-->2)-beta-D-xylopyranoside, named mahuangchiside, II and III were isolated for the first time from the family Gesneriaceae, and IV was isolated for the first time from the genus Chirita.

[A-ring formylated flavonoids and oxoaporphinoid alkaloid from Dasymaschalon rostratum Merr. et Chun].

OBJECTIVE: To study the chemical components in the stem of Dasymaschalon rostratum. METHOD: The components were extracted with solvent, separated and purified with chromatographic methods, identified by NMR, MS, UV, IR and physicol-chemical constants. RESULTS: Three A-ring-formylated flavonoids and one oxoaporphinnoid aikaloid were isolated and identified as lawinal, unonal, isounonal and 7-oxodehydroasimilobine. CONCLUSION: All the four compounds were isolated for the first time from the genus Dasymaschalon. According to all the phytochemistry papers on Annonaceae, A-ring formylated flavonoids in this family were isolated from the genus Desmos for the first time. Thus, it is an interesting discovery in chemotaxonomy which reveals the close relationship between the two genera Desmos and Dasymaschalon.

New tetrasaccharide flavonol glycoside from Epimedium acuminatum.

A new tetrasaccharide flavonol glycoside was isolated from the aerial parts of Epimedium acuminatum, along with three known flavonoids. The structure of the new compound, named acuminatoside [1], was established to be anhydroicaritin-3-O-alpha-L-rhamnopyranosyl(1----2)-alpha-L-rhamno pyranoside-7- O-beta-D-glucopyranosyl-(1----2)-beta-D-glucopyranoside by means of spectroscopic techniques (uv, eims, fdms, fabms, 1H nmr, 1H-1H COSY, 2D-J, 13C nmr, APT, and 1H-13C HETCOR) and chemical methods (acid hydrolysis, enzymatic hydrolysis, and tlc-densitometry). The known compounds were identified as icariin, epimedoside A, and kaempferitrin.

[Acuminatin from the aerial part of Epimedium acuminatum].

A new flavonol glycoside, C27H28O10, mp 151-152 degrees C (MeOH), named acuminatin (I), was isolated from the aerial part of Epimedium acuminatum Franch in addition to four known compounds. By means of UV, FAB-MS, EI-MS, 1HNMR, 13CNMR and chemical evidences, the structure of acuminatin was established as 6", 6"-dimethylpyrano (2", 3": 7, 8) 4'-methyl kaempferol-3-O-alpha-L-rhamnopyranoside. The known compounds were identified as kaempferol-3-O-alpha-L-rhamnopyranoside (II), quercitrin (III), hyperin (IV) and daucosterol (V).